There are no conversations in this channel.
Please log in to your account to view your subscribed posts.
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
1 response
4,007 views
0 reactions
|
by ECO
04-14-2008, 09:14 AM
|
|||
|
2 responses
4,747 views
0 reactions
|
by DNAcowboy
04-09-2008, 10:11 PM
|
|||
|
0 responses
3,588 views
0 reactions
|
by eldfors
04-04-2008, 07:39 AM
|
|||
|
0 responses
3,076 views
0 reactions
|
by lgoff
02-20-2008, 07:22 AM
|
|||
|
0 responses
3,634 views
0 reactions
|
by chrisdag
01-23-2008, 01:33 PM
|
|||
|
1 response
3,799 views
0 reactions
|
by chrisdag
01-23-2008, 01:04 PM
|
No topics found.
-
Next-generation sequencing (NGS) is changing how clinical and public health laboratories detect pathogens, track antimicrobial resistance,...10-01-2026, 05:37 AM -
Much of the genetic basis of Alzheimer's disease and related dementias (AD/ADRD) is still unexplained, and some of the answers may sit...10-01-2026, 05:06 AM
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...Today, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...